about
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort.Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des MyelodysplasiesClinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletionTET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells.A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.Bone Marrow Involvement in Systemic Lupus Erythematosus.Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure.Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis.Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies.
P50
Q33302879-2398960A-9FC2-4303-8FBD-799A4474C099Q33396001-874C6438-5F8A-4DDD-8539-0978BE0CC25AQ33409859-708A4F0E-CE6B-4517-81A8-48C5FA07D3D0Q33439676-24746FDB-DCA1-420F-9AA9-859E13FF5752Q33518976-FAC2BC81-C57B-47D5-A5A1-B1207EEE9EAAQ33836662-793E9D2D-2F93-4883-B54E-3541FC464CACQ34516294-91B63510-4CCA-4EAF-99EC-7932C1467CFEQ36325211-1D9A3E25-EDE4-4B69-86FE-A689F0FE27F8Q37075929-D901BDC5-5D62-4BB7-8FFB-44794D116E66Q37470906-C05EFC72-A3D2-4506-9418-CE88C6F3297DQ37723866-07D0C429-8194-4233-8D48-A5000CFF24D6Q37852242-544BF9AE-CDD5-442D-B4DD-8D53AA638904Q38337411-98212614-1E19-498F-8486-98547734FD20Q38392081-A2B1ECA7-5F9D-443A-9EFF-14D7E6D1BF60Q38774422-B788CCCC-DDAA-4D89-A5F8-0238C91F3F17Q38960280-0CE7C7B3-8137-4CF6-9103-EB4DAF1715C9Q39089892-89B84D95-2707-4592-B004-1D089EF3A818Q40559142-9BC865B0-AF9A-4758-AC86-2C9F09BE5C3CQ41097685-D5A6BEF8-823D-4B8E-85F1-99BFE0D39D46
P50
description
onderzoeker
@nl
name
Odile Beyne-Rauzy
@ast
Odile Beyne-Rauzy
@en
Odile Beyne-Rauzy
@es
Odile Beyne-Rauzy
@nl
Odile Beyne-Rauzy
@sl
type
label
Odile Beyne-Rauzy
@ast
Odile Beyne-Rauzy
@en
Odile Beyne-Rauzy
@es
Odile Beyne-Rauzy
@nl
Odile Beyne-Rauzy
@sl
prefLabel
Odile Beyne-Rauzy
@ast
Odile Beyne-Rauzy
@en
Odile Beyne-Rauzy
@es
Odile Beyne-Rauzy
@nl
Odile Beyne-Rauzy
@sl